| Literature DB >> 29744113 |
Luiza Tonello1, Arthur Paredes Gatti1, João Diedrich Neto1, Uirá Fernandes Teixeira1, Marcos Bertozzi Goldoni1, Paulo Roberto Ott Fontes1, José Artur Sampaio1, Luiz Maraninchi Pereira Lima1, Fábio Luiz Waechter1.
Abstract
The oncogenic hypophosphatemic osteomalacia is a very incapacitating disease and the mortality rate, mainly due to metabolic disorder, depends on the early diagnosis, since the surgery is curative. The major difficulty is to consider this kind of disease in patients with complex clinical presentation. Moreover, medical centers have to provide a good diagnostic infrastructure because these tumors, in most cases, are small and do not have an obvious site. This case report is about a man with a rapid loss of strength and muscle mass, which had his diagnosis in a late, culminating in significant deformities and organic dysfunctions with clinical repercussions. However, the fast diagnosis with appropriate tests determined the stop point of the evolution of disease and marked the beginning of metabolic recovery. This case reinforces the global problem health care infrastructure and the access to diagnostic equipment, demonstrating the impact on the patient's health of our service.Entities:
Year: 2017 PMID: 29744113 PMCID: PMC5934660 DOI: 10.1093/omcr/omx045
Source DB: PubMed Journal: Oxf Med Case Reports ISSN: 2053-8855
Preoperative laboratory exams.
| Exams | Values |
|---|---|
| Total proteins (serum) (NR: 6.0–8.5 g/dl) | 7.2 g/dl |
| Albumin (NR: 3.5–4.8 g/dl) | 4.41 g/dl |
| Alpha-1 globulin (NR: 0.1–0.3 g/dl) | 0.27 g/dl |
| Alpha-2 globulin (NR: 0.5–1.1 g/dl) | 0.76 g/dl |
| Beta-1 globulin (NR: 0.36–0.52 g/dl) | 0.36 g/dl |
| Beta-2 globulin (NR: 1.21–2.70 µg/ml) | 0.40 µg/dl |
| Gamma globulin (NR: 0.5–1.4 g/dl) | 1.00 g/dl |
| Thyroid stimulating hormone (TSH) (NR: 0.5–6,0 μU/ml) | 4.88 μU/ml |
| PTH (NR: 10–65 pg/ml) | 189.2 pg/ml |
| Urinary protein (NR: 0–20 mg/dl) | 0.45 g/dl |
| Anti-nuclear antibody (NR: negative) | Negative |
| Calcium (serum) (NR: 4.4–5.4 mg/dl) | 9.8 mg/dl |
| Inorganic phosphorus (serum) (NR: 3.4–4.5 mg/dl) | 1.7 mg/dl |
| Inorganic phosphorus (urinary) (NR: 400–1.300 mg/24 h) | 681 mg/24 h |
| 25-Hydroxy-vitamin-D (NR: >30.0 ng/ml) | 30 ng/ml |
Figure 1:MRI (inguinal view).
Figure 2:PET-CT.
Figure 3:bone scintigraphy with technetium.
Figure 4:bone scintigraphy with technetium (focus).
Immunohistochemical analysis.
| Antibody | Results |
|---|---|
| Vimentin (V9) | Positive |
| CD 56 (123C3) | Positive |
| CD 99 (12-E7) | Positive |
| CD 34 (QBEnd-10) | Negative |
| CD 57 (TB 01) | Negative |
| S100 automated (p) | Negative |
| Actine ML (1A4) | Negative |
| CKM automated (AE1/AE3/PCK26) | Negative |
| CK 7 automated (SP52) | Negative |
| GFAP (6F2) | Negative |
| NSE (BBS/NC/V I-H14) | Negative |
| Sinaptophisine automated (Sp11) | Negative |
| Ki 67 automated (30–9) | 3% |
Postoperative laboratory exams.
| Exams | Values |
|---|---|
| Total proteins (serum) (NR: 6,0–8.5 g/dl) | 7.4 g/dl |
| Albumin (NR: 3.5–4.8 g/dl) | 4.02 g/dl |
| Alpha-1 globulin (NR: 0.1–0.3 g/dl) | 0.29 g/dl |
| Alpha-2 globulin (NR: 0.5–1.1 g/dl) | 0.93 g/dl |
| Beta-1 globulin (NR: 0.36–0.52 g/dl) | 0.31 g/dl |
| Beta-2 globulin (NR: 1.21–2.70 µg/ml) | 0.67 µg/dl |
| Gamma globulin (NR: 0.5–1.4 g/dl) | 1.18 g/dl |
| Thyroid stimulating hormone (TSH) (NR: 0.5–6,0 μU/ml) | 4.65μU/ml |
| PTH (NR: 10–65 pg/ml) | 59 pg/ml |
| Urinary protein (NR: 0–20 mg/dl) | 4.56 g/dl |
| Anti-nuclear antibody (NR: negative) | Negative |
| Calcium (serum) (NR: 4.4–5.4 mg/dl) | 5.2 mg/dl |
| Inorganic phosphorus (serum) (NR: 3.4–4.5 mg/dl) | 3.8 mg/dl |
| Inorganic phosphorus (urinary) (NR: 400–1.300 mg/24 h) | 729 mg/24 h |
| 25-Hydroxy-vitamin-D (NR: > 30,0 ng/ml) | 38 ng/ml |